US Broker Ratings

GeneDx Holdings Corp. (WGS) Investor Outlook: Strong Buy Ratings and Revenue Surge

GeneDx Holdings Corp. (WGS), a burgeoning force in the healthcare sector, specifically within the Diagnostics & Research industry, is capturing the attention of investors with its..

Belite Bio, Inc (BLTE) Stock Report: Exploring the 112.4 USD Peak Amidst a -17.04% Potential Downside

Investors have their eyes on Belite Bio, Inc (BLTE), a San Diego-based clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for retinal degenerative diseases. Despite its..

Arrowhead Pharmaceuticals (ARWR) Stock Analysis: A Look at the 19.92% Potential Upside

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a promising player in the biotechnology sector, captivating investor interest with its innovative approach to treating intractable diseases. The company,..

Arcutis Biotherapeutics (ARQT) Stock Analysis: Exploring a 25% Potential Upside with Strong Buy Ratings

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is capturing the attention of investors in the healthcare sector, particularly within the biotechnology industry. With a market capitalization of $3.03..

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Biotech Potential with 17.95% Upside

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a prominent player in the biotechnology sector, has been making headlines with its innovative approach to cellular metabolism. As a biopharmaceutical..

Xenon Pharmaceuticals Inc. (XENE): Investor Outlook Shows 34% Upside Potential in Biotech Innovator

Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a Canadian-based biopharmaceutical company specializing in neuroscience, is capturing investor attention with its intriguing growth potential and robust analyst support. Operating..

LeMaitre Vascular, Inc. (LMAT): Investor Outlook with a Promising 20% Upside Potential

LeMaitre Vascular, Inc. (NASDAQ: LMAT), a key player in the healthcare sector, has captured the attention of investors with a compelling 20.37% upside potential, as indicated..

AtriCure, Inc. (ATRC) Stock Analysis: Exploring a 51% Potential Upside with Strong Buy Ratings

AtriCure, Inc. (NASDAQ: ATRC) stands out in the healthcare sector, particularly within the medical instruments and supplies industry. With a market capitalization of $1.69 billion, AtriCure..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling a 73% Potential Upside in the Booming Biotech Arena

Apogee Therapeutics, Inc. (NASDAQ: APGE) is capturing investor attention with its promising pipeline in the biotechnology sector. With a market capitalization of $3.68 billion, this clinical-stage..

Galapagos NV (GLPG) Stock Analysis: Navigating a Challenging Biotech Landscape with Strategic Pipeline Developments

Galapagos NV (NASDAQ: GLPG), a prominent player in the biotechnology sector, has been making waves with its innovative approach to developing medicines in the fields of..

Acadia Healthcare (ACHC) Stock Analysis: Navigating a Challenging Market with a 33% Upside Potential

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) is a prominent player in the healthcare sector, specializing in behavioral healthcare services across the United States and Puerto Rico...

Certara, Inc. (CERT) Investor Outlook: Unpacking the 26% Potential Upside

Certara, Inc. (NASDAQ: CERT) has captured investor attention with its significant potential upside of 26.07%, highlighting a promising opportunity in the health information services industry. As..

Clover Health Investments (CLOV): Investor Outlook Amidst 34% Revenue Growth and Strategic Innovations

Clover Health Investments, Corp (CLOV), a prominent player in the healthcare plans industry, is capturing the attention of astute investors with its robust revenue growth and..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Biotech with a 6.24% Potential Upside and Strong Buy Ratings

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is making waves in the biotechnology sector, offering intriguing opportunities for investors focused on the healthcare industry. With a market capitalization..

Beam Therapeutics Inc. (BEAM) Stock Analysis: Unpacking a 92% Potential Upside in the Biotech Arena

Beam Therapeutics Inc. (NASDAQ: BEAM), a company at the forefront of precision genetic medicine, has caught the attention of investors with its promising portfolio and strategic..

Ardent Health, Inc. (ARDT) Stock Analysis: Exploring a 29.95% Potential Upside in the Healthcare Sector

Ardent Health, Inc. (ARDT), a prominent player in the U.S. healthcare sector, presents an intriguing opportunity for investors with a potential upside of 29.95%. Operating under..

Alignment Healthcare, Inc. (ALHC) Stock Analysis: Exploring a 23.47% Potential Upside

Alignment Healthcare, Inc. (NASDAQ: ALHC) stands out in the healthcare sector with a promising prospect for investors, particularly those looking to tap into the expanding market..

Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Exploring a 18.87% Potential Upside in the Biotech Sector

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stands out in the biotechnology industry with its innovative approach to drug discovery, integrating cutting-edge technology across various scientific disciplines. Headquartered..

NewAmsterdam Pharma (NAMS) Stock Analysis: A 740% Revenue Growth in Focus Amid Biotech Innovation

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a Netherlands-based biotechnology firm, is turning heads in the healthcare sector with its impressive 740.10% revenue growth. As a late-stage..

Concentra Group Holdings Parent (CON) Stock Analysis: Exploring a 44% Upside in Healthcare

Concentra Group Holdings Parent, Inc. (NASDAQ: CON) is an intriguing player in the healthcare sector, particularly within the medical care facilities industry. With a market capitalization..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds